US Patent Issued to Memorial Sloan Kettering Cancer Center on Dec. 2 for "Determinants of cancer response to immunotherapy by pd-1 blockade" (New York Inventors)

ALEXANDRIA, Va., Dec. 2 -- United States Patent no. 12,485,162, issued on Dec. 2, was assigned to Memorial Sloan Kettering Cancer Center (New York).

"Determinants of cancer response to immunotherapy by pd-1 blockade" was invented by Timothy A. Chan (Cortlandt Manor, N.Y.), Naiyer A. Rizvi (New York) and Matthew D. Hellmann (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy."

The patent was filed on March 15, 2021, under Application No. 17/202,173.

*For further information, including images, charts and tables, please visit: ...